Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients. Issue 8 (August 2015)

• Record Type: Journal Article
• Authors: Gómez Peña, Celia; Dávila-Fajardo, Cristina L.; Martínez-González, Luis J.; Carmona-Sáez, Pedro; Soto Pino, María J.; Sánchez Ramos, Jesús; Moreno Escobar, Eduardo; Blancas, Isabel; Fernández, Juan J.; Fernández, Dámaso; Correa, Concepción; Cabeza Barrera, José
• Is Part Of: Pharmaocogenetics and genomics. Volume 25:Issue 8(2015:Aug.)
• Publication Date: 2015-08
• Subjects: Pharmacogenetics -- Periodicals; Pharmacogenomics -- Periodicals; Genetic toxicology -- Periodicals; Biomedical genetics -- Periodicals; 615.7
• DOI: 10.1097/FPC.0000000000000149
• Languages: English
• ISSNs: 1744-6872

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Background</title> <p>The <italic>HER2</italic> 655 A>G genetic variant has recently been associated with trastuzumab-induced cardiotoxicity in HER2 breast cancer patients. Considering previous results, the aim of our study was to validate the role of this polymorphism as a predictor of the cardiac toxicity of trastuzumab in breast cancer patients.</p> </sec> <sec> <title>Methods</title> <p>Our study population was composed of 78 HER2 breast cancer patients receiving trastuzumab. The <italic>HER2</italic> 655 A>G (rs1136201) genetic variant was genotyped using TaqMan allelic discrimination technology. Patients were classified on the basis of the occurrence of cardiotoxic events or the absence of cardiotoxic events during 1 year after the first infusion.</p> </sec> <sec> <title>Results</title> <p>The <italic>HER2</italic> 655 A>G polymorphism was significantly associated with cardiotoxicity: AG versus AA [<italic>P</italic>=0.012, odds ratio (OR)=5.12, 95% confidence interval (CI) 1.43–18.36], AG+GG versus AA (<italic>P</italic>=0.01, OR=5.72, 95% CI 1.50–21.76), AG versus AA+GG (<italic>P</italic>=0.005, OR=7.17, 95% CI 1.82–28.29). A meta-analysis combining these data with the results from previous studies confirmed this association.</p> </sec> <sec> <title>Conclusion</title> <p>Our results support the role of the <italic>HER2</italic> 655 A>G polymorphism as a genetic marker of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients.</p> </sec> </abstract>